Meanwhile, cancer stem cell (CSC) enrichment, an aggressive subpopulation for chemotherapy resistance, was identified in PIK3CA mutation tumors, including CRC [14], and detailed analysis of the pathogenic heterogeneity in PIK3CA-mutant tumors could help explain the differences in L-OHP therapeutic response among individual CRC patients. Here, PIK3CA is linked to colorectal carcinoma.